和黄医药肺癌新药联合疗法上市申请获受理并获纳入优先审评

Core Viewpoint - The new drug application for the combination therapy of Savolitinib and Osimertinib for treating MET amplified EGFR mutation-positive non-small cell lung cancer has been accepted and prioritized for review by the National Medical Products Administration of China [1] Group 1 - The combination therapy has shown potential to improve treatment continuity and quality of life for patients, with multiple late-stage clinical trials currently underway [2] - This therapy aims to address the issue of resistance to EGFR inhibitors, providing an all-oral, chemotherapy-free treatment option [2] Group 2 - The acceptance of this application will trigger milestone payments from AstraZeneca [3]